Completed PHASE3 INTERVENTIONAL 2-arm NCT00927472

Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice

A Multi-Center Phase III Study to Evaluate Ovide Lotion 0.5% Formulation, for the Control of Head Lice in Pediatric Subjects and Adult Subjects With Pediculosis Capitis

Sponsor: Sun Pharmaceutical Industries, Inc.

Conditions Pediculosis

Interventions Malathion gel 0.5% Permethrin 1% rinse

Updated 7 times since 2017 Last updated: Jul 9, 2014 Started: Aug 31, 2009 Primary completion: May 31, 2010 Completion: Jun 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Pediculosis, this trial is completed. The trial is conducted by Sun Pharmaceutical Industries, Inc. and has accumulated 7 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Aug 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Pharmaceutical Industries, Inc.

Data source: Sun Pharmaceutical Industries, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bentonville, United States
• Jonesboro, United States